Free Newsletter
VA marks Avandia off formulary
The bigger they are, the harder they fall? In yet another blow to the embattled diabetes drug Avandia, the Department of Veterans Affairs is severely restricting its use. Until now, the VA accounted for about 8 percent of Avandia sales.
Once upon a time, Avandia delivered $2.2 billion to GlaxoSmithKline's top line in the U.S. alone. Since reports of safety problems surfaced in May, those sales have free-fallen by 60 percent. And more downward pressure may be on its way. Despite an advisory panel's recommendation that it remain on the market, the FDA is still arguing whether to pull the drug.
- read the article from the New York Times
Related Articles:
What to do with Avandia sales force? Report
Expert committee says Avandia should stay. Report
Docs shunning Avandia in wake of safety study. Report
Avandia risks exposed under deal to post data. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: